| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,777 |
1,356 |
$263K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,757 |
3,737 |
$222K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,829 |
4,221 |
$173K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,289 |
1,650 |
$135K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
3,843 |
2,628 |
$130K |
| 81003 |
|
2,703 |
1,986 |
$98K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,730 |
3,502 |
$94K |
| G0378 |
Hospital observation service, per hour |
4,578 |
2,704 |
$71K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,099 |
1,344 |
$68K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,982 |
4,174 |
$67K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,381 |
1,143 |
$62K |
| 82962 |
|
4,213 |
1,430 |
$45K |
| 96368 |
|
2,664 |
1,800 |
$43K |
| 80053 |
Comprehensive metabolic panel |
5,360 |
3,130 |
$30K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,183 |
6,527 |
$27K |
| 84484 |
|
6,231 |
3,996 |
$23K |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,024 |
1,058 |
$22K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,241 |
1,471 |
$21K |
| 71045 |
Radiologic examination, chest; single view |
6,557 |
4,709 |
$18K |
| 80076 |
|
2,486 |
1,747 |
$18K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,607 |
646 |
$17K |
| 36415 |
Collection of venous blood by venipuncture |
6,672 |
3,282 |
$16K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,104 |
874 |
$15K |
| 93041 |
|
6,499 |
4,516 |
$15K |
| 83690 |
|
2,442 |
1,766 |
$15K |
| 85610 |
|
3,977 |
2,775 |
$13K |
| 85730 |
|
3,964 |
2,766 |
$13K |
| 81000 |
|
1,902 |
1,384 |
$10K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
630 |
443 |
$10K |
| 82150 |
|
1,434 |
1,009 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,578 |
1,142 |
$9K |
| 87040 |
|
2,171 |
1,561 |
$7K |
| 82550 |
|
2,061 |
1,476 |
$7K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
151 |
116 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,391 |
741 |
$7K |
| 83880 |
|
1,251 |
879 |
$6K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,135 |
883 |
$5K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,736 |
665 |
$5K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
513 |
362 |
$5K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
186 |
143 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,370 |
975 |
$4K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
282 |
196 |
$4K |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
1,289 |
446 |
$4K |
| 84703 |
|
1,133 |
981 |
$4K |
| 87070 |
|
354 |
259 |
$3K |
| 82803 |
|
503 |
304 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,756 |
1,197 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,046 |
797 |
$3K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
171 |
87 |
$3K |
| 94664 |
|
370 |
214 |
$2K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
313 |
225 |
$2K |
| 83605 |
|
1,448 |
988 |
$2K |
| 87186 |
|
423 |
292 |
$2K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,546 |
1,026 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
493 |
237 |
$1K |
| 86141 |
|
41 |
35 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
632 |
467 |
$1K |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
210 |
141 |
$1K |
| 81001 |
|
1,958 |
1,485 |
$1K |
| 93970 |
|
106 |
72 |
$1K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
31 |
25 |
$1K |
| 96367 |
|
103 |
73 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
46 |
40 |
$993.77 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
27 |
13 |
$739.33 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
96 |
62 |
$718.64 |
| 80061 |
Lipid panel |
616 |
418 |
$658.09 |
| 72131 |
|
65 |
45 |
$617.88 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
49 |
36 |
$601.82 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
36 |
27 |
$589.81 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
121 |
107 |
$580.40 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
15 |
$558.15 |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
72 |
58 |
$448.36 |
| 85379 |
|
445 |
340 |
$432.86 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16 |
15 |
$430.33 |
| 86900 |
|
18 |
12 |
$375.97 |
| 72170 |
|
154 |
100 |
$348.90 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
240 |
122 |
$313.10 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
57 |
41 |
$271.94 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
299 |
202 |
$254.07 |
| 87205 |
|
634 |
472 |
$225.03 |
| 93880 |
|
24 |
14 |
$202.98 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
186 |
112 |
$185.28 |
| 71250 |
|
44 |
28 |
$173.88 |
| 82607 |
|
57 |
36 |
$164.36 |
| J0735 |
Injection, clonidine hydrochloride, 1 mg |
224 |
138 |
$162.53 |
| 83735 |
|
580 |
383 |
$154.70 |
| 86769 |
|
1,311 |
914 |
$133.67 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
127 |
79 |
$119.83 |
| 71046 |
Radiologic examination, chest; 2 views |
32 |
28 |
$111.70 |
| 85652 |
|
81 |
66 |
$100.51 |
| J2060 |
Injection, lorazepam, 2 mg |
105 |
63 |
$88.43 |
| 76770 |
|
18 |
14 |
$52.38 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
171 |
117 |
$29.27 |
| 82553 |
|
169 |
132 |
$12.36 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
817 |
559 |
$11.88 |
| 82746 |
|
18 |
12 |
$11.86 |
| 84436 |
|
141 |
92 |
$11.86 |
| 86850 |
|
37 |
24 |
$8.86 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
41 |
27 |
$7.02 |
| 82947 |
|
164 |
59 |
$3.13 |
| 87081 |
|
433 |
316 |
$2.69 |
| 82570 |
|
38 |
34 |
$1.56 |
| 83615 |
|
39 |
26 |
$0.00 |
| 88342 |
|
157 |
108 |
$0.00 |
| 80320 |
|
26 |
15 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
54 |
15 |
$0.00 |
| 86738 |
|
19 |
14 |
$0.00 |
| 86403 |
|
42 |
42 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
133 |
48 |
$0.00 |
| 82728 |
|
39 |
24 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
232 |
184 |
$0.00 |
| 84100 |
|
51 |
25 |
$0.00 |
| 82805 |
|
19 |
12 |
$0.00 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
51 |
36 |
$0.00 |
| 81025 |
|
146 |
143 |
$0.00 |
| J1956 |
Injection, levofloxacin, 250 mg |
84 |
40 |
$0.00 |
| 83540 |
|
23 |
12 |
$0.00 |